---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-24-000063"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:59:58.781971+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio VTP-300 data: 76% eligible to stop NUC therapy; significant HBsAg reduction vs placebo

## Summary
- HBV003 (Phase 2b): 76% (16/21) eligible for NUC discontinuation; 19% achieved undetectable HBsAg.
- IM-PROVE II (Phase 2a): statistically significant HBsAg reduction at 24 weeks post-EOT (p<0.05) vs placebo.
- 84% of VTP-300 group (16/19) met criteria to discontinue NUC therapy at EOT vs 52% placebo.
- All treatment groups well-tolerated; no SAEs or Grade 3/4 treatment-related AEs in either trial.
- Data cutoffs: April 15, 2024 (HBV003) and April 12, 2024 (IM-PROVE II); presented at EASL Congress 2024.

## SEC filing metadata
- accession: 0001828185-24-000063
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000063/0001828185-24-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000063/brns-20240606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-24-000063
- JSON: https://secwatch.observer/filing/0001828185-24-000063.json
- Plain text: https://secwatch.observer/filing/0001828185-24-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.